Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
Gut bacteria and diet may hold new keys for triple-negative breast cancer care
This narrative review examines the role of gut microbiome composition, antibiotics, obesity, and dietary modulation in triple-negative breas…
A review explores how gut bacteria, antibiotics, and diet could change treatment for triple-negative breast cancer patients.
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
Docetaxel chemotherapy linked to rare heart attack in breast cancer patient
This case report and literature review examines acute myocardial infarction following docetaxel chemotherapy in a patient with triple-negati…
A rare heart attack occurred after docetaxel chemotherapy in a patient with triple-negative breast cancer. This case review suggests the dru…
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
A Hidden Protein in Aggressive Breast Cancer May Unlock New Treatments
This meta-analysis of 12 studies in 1,545 TNBC patients found a pooled NY-ESO-1 expression prevalence of 16.1%. The authors note substantial…
A protein found in about one in six triple-negative breast cancers could open the door to immune-based treatments that target cancer cells w…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
Adding immune drugs to chemo helps early stage triple negative breast cancer patients stay disease free longer
A meta-analysis found neoadjuvant immune checkpoint inhibitors with chemotherapy significantly improved event-free survival but not overall …
A large review of trials found that adding immune checkpoint inhibitors to chemotherapy improves survival chances for early stage triple neg…
Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
Radiofrequency Ablation Offers Breast Cancer Patients a Less Invasive Option
This Phase 3 multicenter study evaluated 370 female patients with early stage breast cancer (Tis-T1, N0M0). Radiofrequency ablation followed…
A new five-year study proves that a needle-based treatment works just as well as removing part of the breast for early stage cancer.
Research across Cancer
Related studies from across the Cancer family.
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema
Lymphedema surgery improves quality of life in breast cancer survivors
This meta-analysis of observational studies found that therapeutic lymphovenous anastomosis (LVA) significantly improves quality of life in …
A new analysis finds that lymphovenous anastomosis significantly boosts quality of life for breast cancer survivors with lymphedema, especia…
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema
Weight loss and virtual reality rank highest for breast cancer swelling and pain relief
This network meta-analysis of 754 patients evaluated non-pharmacological therapies for breast cancer-related lymphedema. Weight reduction ra…
Weight loss and virtual reality training ranked best for reducing arm swelling and pain in breast cancer patients, though other therapies al…
Healthcare professionals need updated guidance on managing breast cancer-related lymphedema effectively today
Review updates care for breast cancer-related lymphedema
This narrative review aims to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regardi…
A new review summarizes the latest understanding of breast cancer-related lymphedema to help healthcare professionals counsel patients.
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Protocol for randomized controlled trial of TEAS pretreatment for breast cancer-related lymphedema
New electrical therapy may stop breast cancer swelling before surgery starts
This document outlines a randomized controlled trial protocol evaluating transcutaneous electrical acupoint stimulation pretreatment in brea…
A new electrical therapy might stop arm swelling before breast cancer surgery begins
Taxane-Based and Long-Course Chemotherapy Linked to Higher Breast Cancer-Related Lymphedema Risk
New Data Links Chemo Drugs to Arm Swelling in Breast Cancer
In a retrospective cohort of 201 breast cancer patients at Guangzhou Red Cross Hospital, taxane-based regimens, long-course chemotherapy, an…
Breast cancer patients on certain chemotherapy drugs face a higher risk of developing arm swelling after treatment ends.
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Review of 35 cases highlights diagnostic challenges in gastric metastasis from invasive lobular breast cancer
Breast Cancer Spreads to Stomach: Why Testing Must Change
This case report and literature review synthesizes data from 35 recent cases (2019–2024) of gastric metastasis from breast cancer.
Doctors must re-test stomach issues in breast cancer patients because the cells often change their identity.
Questions about Hormone Receptor-Positive Breast Cancer
Is trastuzumab deruxtecan better than chemotherapy for HR-positive breast cancer?
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Full answer →Does datopotamab deruxtecan improve survival for Hormone Receptor-Positive Breast Cancer?
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Full answer →All Hormone Receptor-Positive Breast Cancer Articles
- Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
- Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
- Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
- Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
- Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
- Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
- Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
- Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
- Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
- Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
- Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
- Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
- CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
- Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
- Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
- AI-mediated ultrasonic radiomics shows potential for triple-negative breast cancer diagnosis and prognosis
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
- Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
- Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
- Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms
- Adherence to 2021 ABS imaging recommendations in 148 male breast referrals at a UK hospital
- Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
- Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
- Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients
- Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
- Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
- Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
- Phase Ib trial: Mam-A DNA vaccine plus endocrine therapy induces T cells in ER+ breast cancer
- PSMA PET/CT shows uptake in half of metastatic triple-negative breast cancer patients
- Population study links PALB2 variants to increased cancer risk and mortality in two large cohorts
- DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
- Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
- Adjusted Breast Cancer Index model identifies minimal-risk groups in premenopausal HR+ node-negative breast cancer